Back to Research Home
RLXRLX Technology Inc
Health Care · Medicinal Chemicals and Botanical Products · Mid
$1.61−1.83%
As of 23 Oct 2026Mkt cap $2.2B
Stage 13
AVOID
Fundamentals
44.4/75
Technical
5.0/15
Independent
49.4/90
GCAE viewstructural technical damage is a hard non-actionable condition
Price
- 1M
- −5.8%
- 3M
- −21.1%
- 6M
- −28.1%
- 1Y
- −30.6%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- —
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- 2.8%
- Operating margin
- -3.9%
- FCF margin
- 24.9%
- Current ratio
- 5.7x
Growth
- Revenue growth
- +50.3%Latest FY YoY
- Revenue CAGR
- −19.3%
- EPS CAGR
- −18.8%
- FCF CAGR
- −14.3%
Capital
- Share-count trend
- −4.4%3Y annualised
- Net cash
- $742M-4.7x OCF
Annual trend
- CAGR 2021–2025
- −19.3%
- Latest · 2025
- $1B
- YoY
- +50.3%
GCAE Research
- Quality Research
- PRE-AI
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
structural technical damage is a hard non-actionable condition
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-13
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- damaged
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded